Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 400 in its research report dated October 23, 2020.
Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 495 in its research report dated October 23, 2020.
ICICI Direct is bullish on Biocon recommended buy rating on the stock with a target price of Rs 500 in its research report dated October 23, 2020.
Shaw says vaccine candidates will first be approved for emergency use and full approval will come only after evaluating the durability of response.
The employee, Vandana Singh (noticee), general manager regulatory affair of Biocon at the time of investigation and also a designated person, is facing a fine of Rs 3 lakh for violating provisions of Prohibition of Insider Trading (PIT) norms.
It had posted a net profit of Rs 253.8 crore for the July-September quarter previous fiscal, Biocon said in a late-night BSE filing on Thursday.
If the deal — which may value the firm in excess of $3.5 billion — fructifies, it would mark the third successive investment in 2020 for Kiran Mazumdar Shaw-led Biocon Biologics
Cadila is not only a credible Indian pharma striving for a Covid solution, but on a longer time scale is an interesting watch in the large-cap space witnessing a significant transformation in product portfolio.
As per a regulatory filing on BSE, Biocon Biologics India, a subsidiary of Biocon, and Mylan N.V., announced the US launch of Semglee.
Technically we believe the index is expected to swing above the upper bound of the 'Broadening formation (11,377)' & move towards 11,500 zone swiftly.
Biocon is one of the companies looking to create a vaccine to fight COVID-19
Biocon Biologics has raised $105 million so far this calendar year through two primary equity infusions.
The deal for 0.85 percent stake values Biocon Biologics at an equity valuation of Rs 26,250 crore, or $3.5 billion
Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 450 in its research report dated July 25, 2020.
A majority of the members of the task force opined that there was not enough evidence currently to get the drug included in the clinical management protocols for COVID-19, sources said.
Indian drugmakers such as Cipla, Cadila, Lupin, Dr Reddy’s, Sun Pharma and a few small-sized pharma companies such as Laurus Labs may benefit from a likely revamp of US medicare
Considering the unmet medical needs in COVID-19, Itolizumab, an already approved drug of Biocon used for treating psoriasis, was approved for "restricted emergency use" in the treatment of coronavirus by the DCGI recently.
ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 490 in its research report dated July 24, 2020.
The company's revenue from operations rose 15 percent to Rs 1,671 crore versus Rs 1,459 crore.